Pharmaceutical News

RSS

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU).

27 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine.

27 Sep 2013

Study: Antidepressant drugs prove to be effective against SCLC patients

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

27 Sep 2013

Anti-inflammatory drug ibuprofen may fight against certain cancers

Latest research by scientists at the University of Bath has shown why the anti-inflammatory drug ibuprofen might stop certain cancers from developing.

26 Sep 2013

Alliqua enters into distribution agreement with Carolon Health Care Products

Alliqua Inc., a biomedical company offering a suite of drug delivery technologies and wound healing solutions, has entered into an agreement with Carolon Health Care Products through which it will gain both new sales distribution pathways and established customers.

26 Sep 2013

HER2-positive breast cancer patients could now benefit from Herceptin SC injection

From today, patients with a very aggressive form of breast cancer known as HER2-positive, could benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous infusion.

26 Sep 2013

Research shows commonly prescribed statin medicines can adversely affect cognitive function

New research that looked at whether two commonly prescribed statin medicines, used to lower low-density lipoprotein (LDL) or 'bad cholesterol' levels in the blood, can adversely affect cognitive function has found that one of the drugs tested caused memory impairment in rats.

26 Sep 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

Inhibiting use of antibiotics may be more effective in reducing C.diff infection

New ways are needed to fight the infection Clostridium difficile and better use of antibiotics could be key, according to the authors of ground-breaking research.

26 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

Redd Remedies earns Better Nutrition Magazine's Best of Supplements Award for Gouch!

Redd Remedies, a leading provider of natural, condition-specific, health and wellness supplements, is this year's recipient of Better Nutrition Magazine's Best of Supplements Award with its all-natural, gluten-free Gouch!.

25 Sep 2013

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.

25 Sep 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

25 Sep 2013

Cardiome partners with LifePharma to commercialize BRINAVESS in Cyprus

Cardiome Pharma Corp. today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Cyprus.

24 Sep 2013

Majority of Michiganders oppose prescription-only approach on popular medicines containing PSE

The Consumer Healthcare Products Association released the following statement today on a recent poll of Michigan voters conducted by The Tarrance Group and underwritten by CHPA.

24 Sep 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

The National Cancer Institute awarded Chrysalis BioTherapeutics a $1.5 million contract to continue development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. The project is a collaboration between Chrysalis, Baylor College of Medicine, and the University of Texas Medical Branch (UTMB).

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Astrazeneca Licenses 3 X-Chem Drug Discovery Programs

...

24 Sep 2013

Pharmaceutical News

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

Group Health helps protect public from infectious diseases through nationwide network

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

Study: Antidepressant drugs prove to be effective against SCLC patients

Anti-inflammatory drug ibuprofen may fight against certain cancers

Alliqua enters into distribution agreement with Carolon Health Care Products

HER2-positive breast cancer patients could now benefit from Herceptin SC injection

Research shows commonly prescribed statin medicines can adversely affect cognitive function

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Inhibiting use of antibiotics may be more effective in reducing C.diff infection

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Redd Remedies earns Better Nutrition Magazine's Best of Supplements Award for Gouch!

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Cardiome partners with LifePharma to commercialize BRINAVESS in Cyprus

Majority of Michiganders oppose prescription-only approach on popular medicines containing PSE

Quartette tablets now available in U.S. for prevention of pregnancy

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Astrazeneca Licenses 3 X-Chem Drug Discovery Programs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News